Skip to content

This Site is Intended for Healthcare Professionals Only

Search AI Powered

Latest Stories

Twenty-eight new medicines added to DND list

The Department of Health and Social Care (DHSC) has added further 28 new products to the list of ‘Drugs for which Discount is Not Deducted’ (DND) in Part II of the Drug Tariff from 1 August 2022.

PSNC said, “It will continue its work to assess whether other drugs and appliances fulfil the current DND entry requirements under either the ‘Group’ and ‘Individual item’ criteria and make applications to NHSBSA and DHSC, accordingly.”


The 28 products added to DND list on 1 August 2022:

  • Adrenaline (base) 500micrograms/0.5ml (1 in 1,000) solution for injection ampoules
  • Amantadine 50mg/5ml oral solution sugar free
  • Amiloride 5mg / Bumetanide 1mg tablets
  • Cabergoline 1mg tablets
  • Cabergoline 2mg tablets
  • Chloral hydrate 500mg/5ml oral solution
  • Doxepin 10mg capsules
  • Efmody 10mg modified-release capsules
  • Efmody 5mg modified-release capsules
  • Ephedrine hydrochloride 15mg tablets
  • Ephedrine hydrochloride 30mg tablets
  • Hydrocortisone 0.5% ointment
  • Liothyronine 10microgram capsules
  • Liothyronine 20microgram capsules
  • Liothyronine 5microgram capsules
  • Naproxen 125mg/5ml oral suspension sugar free
  • Ontozry 100mg tablets
  • Ontozry 12.5mg/25mg tablets treatment initiation pack
  • Ontozry 150mg tablets
  • Ontozry 200mg tablets
  • Ontozry 50mg tablets
  • Potassium dihydrogen phosphate 13.6% (potassium 10mmol/10ml) solution for infusion 10ml ampoules
  • Prednsiolone sodium phosphate 5mg suppositories
  • Procyclidine 10mg/2ml solution for injection ampoules
  • Rupatadine 10mg tablets
  • Tamoxifen 40mg tablets
  • Vazkepa 998mg capsules

A total of 529 products have been granted DND status following checks made by PSNC within the past 26 months.

More For You

A woman using a period tracker app

Cambridge University academics have flagged concerns over the safety of period tracker apps

Pic credit: iStock

Users of period tracking apps face privacy, safety risk, say experts

The report said the apps provide a "gold mine" of data for consumer profiling and warn that in the wrong hands it could pose a safety risk

CAMBRIDGE UNIVERSITY academics have flagged concerns over the safety of period tracker apps and warned that the women using them could face privacy and safety risks.

Keep ReadingShow less
Patients to get test results via NHS app

An investment of £50m has been made to upgrade the NHS app

Patients to get test results via NHS app

Millions of patients will now be able to access test results and get appointment reminders on their smartphones as the government tries to position the NHS app as the default mode of communication and steer away from traditional methods like letters.

An investment of £50m has been made to upgrade the NHS app and the health service hopes to save £200m over the next three years.

Keep ReadingShow less
Health minister assures House of Lords on measures to tackle UK-wide Creon drug shortage

Baroness Merron

Government taking steps to mitigate shortage of cancer drug Creon

Baroness Merron on Monday (9) assured the House of Lords that the government is taking measures to mitigate the shortage of pancreatic cancer drug Creon across the country.

Raising the issue, Baroness Margaret Ritchie wanted to know about the steps being taken by the government to ease the misery of patients suffering from pancreatic cancer.

Keep ReadingShow less
Janet Morrison: "Eventual outcome of spending review needs to tackle pharmacy underfunding"

Janet Morrison

Janet Morrison: "Eventual outcome of spending review needs to tackle pharmacy underfunding"

Community Pharmacy England (CPE) chief executive Janet Morrison has welcomed chancellor Rachel Reeves announcement today that day-to-day spending on the NHS will increase by £29bn a year but insisted that it must reflect in securing the future of pharmacy.

Reeves also revealed that the government will be increasing the NHS technology budget by almost 50 per cent, with £10bn of investment to "bring our analogue health system into the digital age, including through the NHS app".

Keep ReadingShow less
Lynsey Cleland named GPhC chief standards officer

Lynsey Cleland

Pic credit: X

Lynsey Cleland named GPhC chief standards officer

The General Pharmaceutical Council (GPhC) has brought back Lynsey Cleland to lead on a number of important departments in the role of chief standards officer.

Cleland had previously held a number of senior positions at GPhC, including director of Scotland.

Keep ReadingShow less